YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Profound Medical Corp. Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO® Agreement provides Profound with in…
AI data centers are drawing political fire for their heavy energy use, yet demand for computing power keeps building. That same tension is playing out in healthcare, where Canadian companies using artificial intelligence to read scans, sup…
Global debt costs are climbing, with interest bills now larger than many governments spend on AI itself. That squeeze on public budgets is pushing attention toward private companies building real AI tools that healthcare providers can pay…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer and Chairman - Arun Swarup MenawatPresident - Mathieu BurtnykChief Commercial Officer - Tom TamberrinoCorporate Controller…
Key Points Interested in Profound Medical? Here are five stocks we like better. Q2 revenue rose 12% to CAD 2.5 million, but about CAD 3.1 million in TULSA shipments moved from June into July; excluding the timing issue, revenue would have…
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Profound Medical (PROF) shares soared 8.2% in the last trading session to close at $7.37. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.3% gain over the pas…
Grow Funds, an investment Advisor, released its Q1 2026 investor letter for "GROW Small Cap Equity Long/Short Fund". A copy of the letter can be downloaded here. In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outpe…
Telix Pharmaceuticals Limited Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and post-treatment moni…
Profound Medical logo Key Points Interested in Profound Medical? Here are five stocks we like better. Profound Medical’s Q1 revenue more than doubled to about CAD 5.3 million, with gross margin holding at 72% and the net loss narrowing to…
Profound Medical (PRN.TO, PROF) was last seen down 8.5%% in after-hours New York trade after the com PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Profound Medical Corp. – Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORONTO, May 07, 202…
TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies fo…
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies fo…
– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment demonstrates a meaningful and statis…
Earnings Call Insights: Profound Medical Corp. (PRN:CA) Q4 2025 MANAGEMENT VIEW * Arun Menawat, Chairman & CEO, emphasized the completion of recruitment for CAPTAIN, the first multicenter, randomized, controlled trial comparing a new techn…
Profound Medical logo Key Points Q4 results: Profound reported revenue of $6.0 million in Q4 2025 ( $2.3M recurring, $3.7M capital), a 43% YoY increase, while gross margin fell to 67% and the company posted a Q4 net loss of CAD 8.2M with C…
The market expects ARS Pharmaceuticals, Inc. (SPRY) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessin…
Acadia Healthcare (ACHC) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring it…
TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian inv…
* Profound Medical (NASDAQ: PROF [https://seekingalpha.com/symbol/PROF]) on Wednesday had increased its December 19, 2025, private placement to allow participation by a long-term existing investor, with gross proceeds of up to $6.45M from…
TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025…
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offeri…
TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
(RTTNews) - Profound Medical Corp. (PROF), Friday announced the launch of its TULSA-AI Volume Reduction module for benign prostatic hyperplasia (BPH) and the presentation of new clinical data on its incision-free TULSA Procedure at the Rad…
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
(RTTNews) - Profound Medical corp. (PROF) announced earnings for third quarter that Dropped, from last year The company's earnings came in at $7.97 million, or $0.26 per share. This compares with $9.36 million, or $0.38 per share, last yea…
TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
الاتفاقية تفتح المجال أمام علاجات Profound التي لا تستلزم أي جراحة أو إشعاع لاستئصال الأنسجة المريضة، لتخترق بذلك أكبر سوق للرعاية الصحية في الشرق الأوسط تم الحصول بالفعل على جميع الموافقات التنظيمية اللازمة لاستيراد وبيع تقنيتي الاستئصال…
TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for…
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided,…
TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies f…
* Profound Medical (NASDAQ:PROF [https://seekingalpha.com/symbol/PROF]) announced [https://seekingalpha.com/pr/20256714-profound-medical-achieves-record-preliminary-unaudited-revenue-for-the-2025-third-quarter] on Tuesday preliminary unaud…
TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies f…
In trading on Thursday, shares of Stifel Financial Corporation's 4.50% Dep Shares Non-Cumulative Preferred Stock Series D (Symbol: SF.PRD) were yielding above the 6% mark based on its quarterly dividend (annualized to $1.125), with shares…